Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide
continuous therapy as maintenancetreatment after transplant.
Phase:
Phase 2
Details
Lead Sponsor:
European Myeloma Network
Collaborators:
Celgene Corporation EMN Research Italy Impresa Sociale Srl Healt Data Specialists - HeaDS (CRO)